Cam Gallagher
Founder at ZENTALIS PHARMACEUTICALS, INC.
Net worth: 7 M $ as of 2024-04-29
Profile
Cam S.
Gallagher is the founder of Nerveda LLC (founded in 2007), DioGenix, Inc. (founded in 2008), and Zentalis Pharmaceuticals, Inc. (founded in 2014).
He holds the title of Managing Director at Nerveda LLC, Chairman at DioGenix, Inc., and President, CFO, Treasurer & Director at Zentalis Pharmaceuticals, Inc. Currently, Mr. Gallagher is the Chairman at Ocuphire Pharma, Inc. (since 2019), Director at selectION, Inc. (since 2018), Venture Partner at Mesa Verde Ventures LLC, and General Partner at Velosity Capital (since 2021).
He has also held former positions such as Marketing Director at CV Therapeutics, Inc. (2004), Director & Chief Business Officer at RetroSense Therapeutics LLC (2014-2016), Independent Director at Sorrento Therapeutics, Inc. (2012-2014), Director & Vice President-Corporate Development at Oncternal Oncology, Inc., Director at OcuSub, Inc. (2019-2020), Director at Immusoft Corp.
(2022-2024), Director at VelosBio, Inc. (2017-2020), Director at Healios KK (2022-2023), Director & Head-Corporate Development at Oncternal Therapeutics, Inc. (2016-2019), Executive Director at Ray Therapeutics, Inc. (2021-2023), Sales Management & Marketing Executive at Dura Pharmaceuticals, Inc. (2004), Vice President-Marketing at Verus Pharmaceuticals, Inc. (2004-2007), Senior Vice President-Business Development at Neurelis, Inc., Chief Business Officer at jCyte, Inc. (2019-2020), Chief Business Officer at Kalyra Pharmaceuticals, Inc. (2013-2024), and Chief Business Officer at Immusoft Corp.
(2018-2022).
Mr. Gallagher's education includes an undergraduate degree from The Ohio University (1992) and an MBA from the University of San Diego (1997).
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-05-30 | 633,680 ( 0.89% ) | 7 M $ | 2024-04-29 | |
OCUPHIRE PHARMA, INC.
0.14% | 2024-04-14 | 35,904 ( 0.14% ) | 55 113 $ | 2024-04-29 |
Cam Gallagher active positions
| Companies | Position | Start |
|---|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Founder | 2014-12-22 |
| OCUPHIRE PHARMA, INC. | Chairman | 2019-11-30 |
Mesa Verde Ventures LLC
 Mesa Verde Ventures LLC Investment ManagersFinance Mesa Verde Ventures LLC (Mesa Verde Ventures) is a venture capital firm founded in 2006. The firm is headquartered in San Diego, California. | Private Equity Investor | - |
selectION, Inc.
 selectION, Inc. BiotechnologyHealth Technology selectION, Inc. provides a technology platform to develop peptide blockers for ion channels. The company was founded by Andreas Klostermann and is headquartered in San Diego, CA. | Director/Board Member | 2018-05-31 |
Former positions of Cam Gallagher
| Companies | Position | End |
|---|---|---|
Immusoft Corp.
 Immusoft Corp. Medical/Nursing ServicesHealth Services Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA. | Director/Board Member | 2024-02-29 |
Kalyra Pharmaceuticals, Inc.
 Kalyra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Kalyra Pharmaceuticals, Inc. manufactures small molecule drugs. The company was founded by Brian T. Dorsey, Cam L. Garner and Kevin Bunker and is headquartered in San Diego, CA. | Corporate Officer/Principal | 2023-12-31 |
Ray Therapeutics, Inc.
 Ray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation. | Director/Board Member | 2023-04-30 |
| HEALIOS K.K. | Director/Board Member | 2023-02-28 |
Immusoft Corp.
Immusoft Corp. Medical/Nursing ServicesHealth Services Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA. | Corporate Officer/Principal | 2022-04-30 |
Training of Cam Gallagher
| The Ohio University | Undergraduate Degree |
| University of San Diego | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| SORRENTO THERAPEUTICS, INC. | Health Technology |
| HEALIOS K.K. | Health Technology |
| ONCTERNAL THERAPEUTICS, INC. | Health Technology |
| ZENTALIS PHARMACEUTICALS, INC. | Health Technology |
| OCUPHIRE PHARMA, INC. | Health Technology |
| Private companies | 16 |
|---|---|
Dura Pharmaceuticals, Inc.
 Dura Pharmaceuticals, Inc. BiotechnologyHealth Technology Dura Pharmaceuticals, Inc. markets and sells prescription products that treat infectious and respiratory diseases. Dura focuses on products and transactions that leverage its sales and marketing organization. Dura also intends, through the use of collaborative relationships, to develop the Spiros® motorized blisterdisk and Spiros® S2 pulmonary drug delivery systems for the local and systemic delivery of a wide range of medications. It is located in San Diego, CA. | Health Technology |
CV Therapeutics, Inc.
 CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Health Technology |
Verus Pharmaceuticals, Inc.
 Verus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Verus Pharmaceuticals, Inc. was provided pediatric-oriented pharmaceutical products. The company was founded by David A. Socks, James Carroll Blair, Robert W. Keith, Cam L. Garner and David F. Hale in 2002 and was headquartered in San Diego, CA. | Health Technology |
Mesa Verde Ventures LLC
Mesa Verde Ventures LLC Investment ManagersFinance Mesa Verde Ventures LLC (Mesa Verde Ventures) is a venture capital firm founded in 2006. The firm is headquartered in San Diego, California. | Finance |
Nerveda LLC
 Nerveda LLC BiotechnologyHealth Technology Nerveda LLC develops pharmaceutical and diagnostic technologies and drugs for neurological disorders. The company was founded by Cam Gallager in June 2007 and is headquartered in San Diego, CA. | Health Technology |
RetroSense Therapeutics LLC
 RetroSense Therapeutics LLC Medical SpecialtiesHealth Technology RetroSense Therapeutics LLC provides biotechnology services. It offers gene therapies to restore vision in patients suffering from blindness due to retinitis pigmentosa and advanced dry age-related macular degeneration. The company was founded by Sean Ainsworth in 2009 and is headquartered in Ann Arbor, MI. | Health Technology |
Kalyra Pharmaceuticals, Inc.
Kalyra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Kalyra Pharmaceuticals, Inc. manufactures small molecule drugs. The company was founded by Brian T. Dorsey, Cam L. Garner and Kevin Bunker and is headquartered in San Diego, CA. | Health Technology |
Immusoft Corp.
Immusoft Corp. Medical/Nursing ServicesHealth Services Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA. | Health Services |
DioGenix, Inc.
 DioGenix, Inc. Medical SpecialtiesHealth Technology DioGenix, Inc. develops and commercializes novel, non-invasive diagnostic, prognostic and treatment response monitoring tests. Its program is designed to provide neurologists with a comprehensive set of clinical tests to diagnose early-stage MS, segment MS patients into clinical sub-types and predict response to treatment, all using non-invasive blood tests. The company was founded by Cam Gallagher, Douglas W. Bigwood and Larry M. Tiffany in September 2008 and is headquartered in Gaithersburg, MD. | Health Technology |
Neurelis, Inc.
 Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA. | Health Technology |
selectION, Inc.
selectION, Inc. BiotechnologyHealth Technology selectION, Inc. provides a technology platform to develop peptide blockers for ion channels. The company was founded by Andreas Klostermann and is headquartered in San Diego, CA. | Health Technology |
Oncternal Oncology, Inc.
 Oncternal Oncology, Inc. Pharmaceuticals: MajorHealth Technology Oncternal Oncology, Inc. is a clinical-stage oncology company, which engages in the development of novel therapies for both rare and common cancers. The company was founded by Lauren Otsuki and Cam L. Garner and is headquartered in San Diego, CA. | Health Technology |
VelosBio, Inc.
 VelosBio, Inc. Miscellaneous Commercial ServicesCommercial Services VelosBio, Inc. operates as an biopharmaceutical company. It developes antibody-drug conjugates to treat hematological cancers and solid tumors. The company was founded in 2017 and is headquartered in San Diego, CA. | Commercial Services |
OcuSub, Inc.
 OcuSub, Inc. BiotechnologyHealth Technology OcuSub, Inc. engages biotechnology services. It specializes in eye disorder treatment. The company was founded by Mina Patel Sooch, Alan R. Meyer, and William H. Pitlick in 2018 and is headquartered in Farmington Hills, MI. | Health Technology |
jCyte, Inc.
 jCyte, Inc. Medical/Nursing ServicesHealth Services jCyte, Inc. engages in the provision of retinal therapies. Its therapy focuses with retinitis pigmentosa, and retinal progenitor cells. The company was founded by Terry O?Neal, Henry Klassen and Jing Yang in 2012 and is headquartered in Newport Beach, CA. | Health Services |
Ray Therapeutics, Inc.
Ray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation. | Commercial Services |
- Stock Market
- Insiders
- Cam Gallagher
